ProfessorHaydn Walters

Emeritus Professor

Medicine

  • Emeritus Professor
    Medicine

FUNDED PROJECTS

  • GRANT
    Lung cancer screening in Tasmania
    1 Jan 2022 - 31 Oct 2023
    People funded by this grant:
    • Palmer A,
    • Harkness N,
    • de Graaff B,
    • Walters H,
    • Cox I
    Project Total: $24,945; Tasmania has the second highest rate of lung cancer incidence and mortality in Australia. This project will evaluate risk models for identification of high-risk candidates for lung cancer screening and assess whether a screening programme can be effectively and economically implemented. This will lead to earlier identification and treatment, with higher survival rates for Tasmanians, with potential for cost savings. Funded by: Royal Hobart Hospital Research Foundation - Grant-Project ($24,945); University of Tasmania.
  • GRANT
    Providing translatable evidence to advance prevention and management of COPD: a longitudinal study from the 1st to 7th decade of life
    1 Jan 2021 - 31 Dec 2026
    People funded by this grant:
    • Dharmage S,
    • Walters H
    Project Total: $2,893,320; Funding to undertake the 7th decade follow up of the Tasmanian Longitudinal Respiratory Health Study, with an emphasis on lifetime risks for obstructive airways conditions and biomarkers for these. This phase will incorporate high resolution chest CT scanning with AI/computer analysis of lung and airway tissue, as well as state of art physiological assessment of small airway dysfunction Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Clinical Trial and Cohort Studies; University of Tasmania.
  • GRANT
    Association between bush fire-smoke/wood-smoke and hospital usage in Tasmania
    1 Jan 2020 - 31 Jul 2021
    People funded by this grant:
    • Johnston F,
    • de Graaff B,
    • Palmer A,
    • Harkness N,
    • Walters H
    Project Total: $10,000; Poor air quality (indoor and outdoor) has been shown to increase morbidity in populations and as a result increase use of health resources. This study will evaluate the association between bush fire-smoke/ wood-smoke and hospital use in Tasmania. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($10,000); University of Tasmania.
  • GRANT
    Evaluation of new therapeutic targets in idiopathic pulmonary fibrosis (IPF): insights from Australian IPF registry tissue analysis
    1 Jan 2019 - 30 Jun 2022
    People funded by this grant:
    • Sohal S,
    • Walters H,
    • Myers S,
    • Geraghty D,
    • Chia C
    Project Total: $72,727; IPF is a highly destructive lethal disease of the lungs, but with very little information available on the underlying mechanisms. We are going to explore the process of epithelial cell plasticity (or EMT) and a similar process in blood vessel endothelium (Endo-MT). This work will lead to improved diagnosis and treatment of this nasty lung condition. The project brings together well-characterized patients from the Australian IPF registry, blood samples we have collected from them and innovative techniques to reset thinking about the underlying pathological processes active in this illness. Funded by: Clifford Craig Foundation - Grant ($72,727); University of Tasmania.
  • GRANT
    Circulatory biomarkers for Idiopathic Pulmonary Fibrosis: improving patient outcomes
    1 Jan 2018 - 31 Dec 2020
    People funded by this grant:
    • Moodley Y,
    • Corte T,
    • Knight D,
    • Reynolds P,
    • Walters H
    Project Total: $830,005; Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Project; University of Western Australia; University of Tasmania.
  • GRANT
    Epithelial mesenchymal transition (EMT) in the lungs and airways in Idiopathic Pulmonary Fibrosis (IPF)
    1 Jan 2018 - 28 Feb 2020
    People funded by this grant:
    • Sohal S,
    • Walters H,
    • Myers S,
    • Ahuja K,
    • Chia C
    Project Total: $48,354; IPF is a highly destructive lethal disease of the lungs, but with very little information available on the underlying mechanisms. We are going to explore the process of epithelial cell plasticity (or EMT) and a similar process in blood vessel endothelium (Endo-MT). This work will lead to improved diagnosis and treatment of this nasty lung condition. The project brings together well-characterized patients from the Australian IPF registry, blood samples we have collected from them and innovative techniques to reset thinking about the underlying pathological processes active in this illness. Funded by: Clifford Craig Foundation - Grant ($48,354); University of Tasmania.
  • GRANT
    Investigating enantioselectivity of terbutaline and the application to doping control
    31 Oct 2017 - 31 Oct 2019
    People funded by this grant:
    • Jacobson G,
    • Hostrup M,
    • Nichols D,
    • Walters H
    Project Total: $126,133; Beta2-agonists are among the most commonly used drugs by athletes, which is related to the high prevalence of asthma and exercise induced bronchoconstriction in this population. Though use of beta2-agonists is restricted by the World Anti-doping Agency (WADA) in and out of competition, salbutamol, salmeterol, and formoterol are allowed by inhalation within defined therapeutic thresholds. Because of potential performance-enhancing effects of systemic oral use of beta2-agonists, urinary thresholds and decision limits have been established for salbutamol and formoterol to discriminate therapeutic inhaled use from prohibited misuse. However, while the introduction of urinary thresholds and decision limits for salbutamol and formoterol is an innovative way to avoid excessive use by athletes and to lessen the economic burdens associated with therapeutic use exemption (TUE) applications, no thresholds exist for salmeterol and terbutaline. Especially for terbutaline, a urine threshold is relevant, since high dose inhalation and oral ingestion of terbutaline may enhance sprint performance and muscle strength when used acutely and for a longer duration. This project focuses on two ongoing research areas of beta2-agonists; salmeterol where there is currently no urine threshold, and terbutaline, a short acting beta2-agonist widely used in Europe but currently prohibited, which accounts for 76% of adverse analytical findings (AAFs) of beta2-agonists in doping control. Funded by: World Anti-Doping Agency - Grant ($126,133); University of Tasmania.
  • GRANT
    Centre of Research Excellence in Pulmonary Fibrosis
    1 Mar 2017 - 31 Mar 2023
    People funded by this grant:
    • Corte T,
    • Knight D,
    • Laurent G,
    • Holland A,
    • Chambers D
    Project Total: $2,498,606; The Centre for Research excellence in Pulmonary Fibrosis (CRE-PF) aims to develop a sustainable nation-wide network, consisting of world recognized experts. The group will enable an integrative approach to solving PF through a layered strategy extending from molecules germane to disease pathogenesis, to human studies. With this approach the CRE-PF will set a new paradigm for synergy between academia, health care, health policy and the public, placing Australia at the forefront of innovation. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Centre of Research Excellence; University of Sydney; University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Identifying the Underlying Genetic Drivers of IPF using Complementary Approaches
    1 Jan 2017 - 31 Dec 2024
    People funded by this grant:
    • Dickinson J,
    • Corte T,
    • Holloway A,
    • Charlesworth J,
    • Walters H
    Project Total: $1,481,558; In the first instance the goal is to define the contribution of genetic variants to IPF in the Australian population, and we are in a unique position in Australia through our collaboration with Professor Schwartz. Our focus in this particular project is on rare genetic variation, and whilst it is likely that common variation will be similar to other mostly Caucasian populations there are likely to be differences in the rare variants in genes contributing to disease in the different populations. It is therefore important that these types of studies are performed in our population if we are going to understand the biology of disease in our patients. As discussed the identification of rare variants underpinning complex disease is proving fruitful both in understanding the biology of disease, the spectrum of clinical manifestations observed and importantly providing new potential targets for therapy. Funded by: Lung Foundation Australia ($1,481,558); University of Tasmania.
  • GRANT
    Optimising Respiratory Care in Dementia (ORCID): an educational program for carers
    1 Jun 2016 - 20 Nov 2017
    People funded by this grant:
    • Doherty K,
    • Robinson A,
    • Walters H,
    • Elliott K-E
    Project Total: $45,799; Managing chronic respiratory conditions in residential aged care is challenging, particularly for residents with dementia. In pilot studies, we have shown that respiratory conditions are often underdiagnosed and undertreated. Carers are well placed to observe and respond to changes in respiratory health but their knowledge of respiratory care is limited and the recognition, treatment and management of respiratory conditions is not well understood. In collaboration with Aged Care staff and respiratory experts, we will develop an educational module: Optimising Respiratory Care in Dementia (ORCID), to address this deficit in knowledge. Once developed, we will examine the impact this has on the dementia and respiratory knowledge of a group of carers and nurses in a pilot trial. A better approach to respiratory care in dementia will ultimately improve the quality of life of residents and allow the development of a systematic approach to observation, review and referral for residents with respiratory needs. Funded by: Dementia Collaborative Research Centre - Grant-Project ($45,799); University of Tasmania.
  • GRANT
    Occupational and Environmental Exposures Associated with Idiopathic Pulmonary Fibrosis in Australia
    1 Mar 2016 - 31 Aug 2017
    People funded by this grant:
    • Abramson M,
    • Walters H,
    • Corte T
    Project Total: $282,761; Idiopathic pulmonary fibrosis (IPF) is a progressive scarring lung disease of unknown aetiology with little effective treatment and a median survival time of 2-3 years. IPF is a relatively rare disease however in public health terms IPF-related mortality is similar in magnitude to many high priority malignancies including non-Hodgkin's lymphoma, renal cancer and esophageal cancer. We propose to undertake a nationwide case-control study to identify occupations and exposures associated with the development of idiopathicpulmonary fibrosis in Australia. The study will be performed in collaboration with the Australian Idiopathic Pulmonary Fibrosis Registry (AIPFR), supported by the Lung Foundation of Australia. A multi-disciplinary expert team validates registry cases of IPF in accordance with current international guidelines. Population-based controls (frequency matched for age and gender) will be recruited and analysis performed by a team of investigators who are highly experienced in undertaking large epidemiological studies. Epidemiological studies of relatively rare diseases such as IPF can be problematic, predominantly due to the difficulty of genuine case ascertainment. Utilisation of well-validated registry cases in this study allows an exceptional opportunity to study this disease. This will be the largest case-control study ever performed (600 cases) to investigate the association between occupational and environmental exposures and IPF. At a time of advances in biological and therapeutic studies of this disease, the results will be of international significance. Identification of occupational and environmental risk factors in Australia will influence public health policy recommendations to control these exposures and over time reduce the occurrence of this devastating lung disease. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Project; University of Tasmania.
  • GRANT
    Supporting respiratory research
    1 Jan 2016 - 31 Dec 2017
    People funded by this grant:
    • Canny B,
    • Walters H,
    • Zosky G,
    • O'Toole R,
    • Ferguson S
    Project Total: $100,000; This donation is intended to support the work of the 'Breathe Well' NHMRC CRE, based in the School of Medicine. The Centre's NHMRC funding concludes this year. In particular, the donation is to support the completion of PhD projects and fund strategic research involving collaboration between respiratory researchers in the Faculty. This will enable the researchers to seek further NHMRC funding. Funded by: Donation via University of Tasmania Foundation - Donation ($100,000); University of Tasmania.
  • GRANT
    What perinatal risk factors are associated with impaired lung function in children at the age of 6 to 8 years?
    1 Jan 2016 - 30 Sep 2019
    People funded by this grant:
    • Weber H,
    • Shires L,
    • Walters H,
    • Dharmage S
    Project Total: $14,601; The aim of the study is to determine perinatal risk factors that are associated with impaired lung function in early childhood years (6 to 8 years). Funded by: Clifford Craig Foundation - Grant ($14,601); University of Tasmania.
  • GRANT
    Enantioselective pharmacokinetics of formoterol and application to doping control
    12 Oct 2015 - 30 Jun 2019
    People funded by this grant:
    • Jacobson G,
    • Walters H,
    • Nichols D
    Project Total: $195,350; The objectives of this project are to improve windows of detection of formoterol doping using enantioselective urine analyses. Funded by: World Anti-Doping Agency - Grant ($195,350); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    The effect of currently used COPD pharmacological agents on Platelet Activating Factor re-ceptor (PAFr) expression in human epithelial cell culture systems from smokers and COPD
    1 Oct 2015 - 30 Jun 2017
    People funded by this grant:
    • Walters H,
    • O'Toole R,
    • Sohal S
    Project Total: $50,000; PAFr is a key gateway for infection of the lower respiratory tract in COPD with Streptococcus pneumoniae and Haemophilus influenzae and represents a viable anti-infective therapeutic tar-get in this disease to block progression and acute exacerbations. Funded by: Boehringer Ingelheim International GMBH ($50,000); University of Tasmania.
  • GRANT
    Ageing lungs in European cohorts
    1 Jul 2015 - 30 Jun 2020
    People funded by this grant:
    • Walters H,
    • Dharmage S,
    • Mishra G,
    • Abramson M,
    • Gurrin L
    Project Total: $470,343; Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-European Union Collaborative Research; University of Tasmania.
  • GRANT
    The Concave Pattern of the Flow-Volume Curve
    1 Apr 2015 - 1 Apr 2016
    People funded by this grant:
    • Johns D,
    • Walters H
    Project Total: $5,000; This project will assess new mathematically derived indices of lung function to determine whether they are more sensitive to the early effects of lung disease than conventional indices. Funded by: Lung Foundation Australia - Grant ($5,000); University of Tasmania.
  • GRANT
    Epithelial mesenchymal transition (EMT) in the lungs of patients with chronic obstructive pulmonary disease (COPD) and lung cancer undergoing thoracotomy: role in both airway fibrosis and lung cancer
    24 Jul 2014 - 30 Sep 2015
    People funded by this grant:
    • Sohal S,
    • Walters H,
    • Hunter C,
    • Hardikar A
    Project Total: $13,000; Small airway fibrosis is the main contributor to physiological airway obstruction in chronic obstructive pulmonary disease (COPD). The other main airway pathology in COPD is lung cancer as up to 70% of smoking related lung cancer occurs in mild-moderate COPD. Epithelial mesenchymal transition (EMT) may underlie both pathological features and if true, will open up major new therapeutic possibilities. This project aims to investigate EMT in small and matching large airways of smokers/COPD. Funded by: Royal Hobart Hospital Research Foundation - Grant-Clinical Research ($13,000); University of Tasmania.
  • UTAS INTERNAL FUNDING
    Clinical Redesign of respiratory pathways in residential aged care
    14 May 2014 - 30 Oct 2015
    People funded by this grant:
    • Bell E,
    • Robinson A,
    • Walters H,
    • Palmer A,
    • Winter R
    Project Total: $80,000; Respiratory conditions are a leading cause of unplanned admissions from residential aged care and the wider community. This project aims to reduce the burden of preventable unplanned admissions from aged care facilities and improve health outcomes. Funded by: University of Tasmania; University of Tasmania.
  • GRANT
    Enantioselective pharmacokinetics of salbutamol and application to doping control
    31 Mar 2014 - 31 Oct 2017
    People funded by this grant:
    • Jacobson G,
    • Walters H
    Project Total: $139,880; We will apply our advanced analytical technique that can measure both R- and S-salbutamol in urine, to samples from patients treated with either oral or inhaled therapy over the course of a week. The project will validate the benefits, namely increased sensitivity and reduced false positives and false negatives, of measuring R- and S-salbutamol enantiomers. This will allow to better discriminate between oral and inhaled salbutamol. Funded by: World Anti-Doping Agency - Grant ($139,880); University of Tasmania.
  • GRANT
    Clinical Redesign of respiratory pathways in residential aged care
    University of Tasmania1 Mar 2014 - 30 Apr 2015
    People funded by this grant:
    • Bell EJ,
    • Robinson AL,
    • Walters EH,
    • Palmer AJ,
    • Winter RE
    Project Total: $80,000; Respiratory conditions are a leading cause of unplanned admissions from residential aged care and the wider community. This project aims to reduce the burden of preventable unplanned admissions from aged care facilities and improve health outcomes. Funded by: University of Tasmania vTAHSP Demonstration Projects ($80,000)
  • GRANT
    Identification of Progressive Disease in Idiopathic Pulmonary Fibrosis
    1 Jan 2014 - 31 Dec 2017
    People funded by this grant:
    • Corte T,
    • Sohal S,
    • Walters H,
    • Hopkins P,
    • Goh N
    Project Total: $655,209; This project aims to develop a national registry of Idiopathic Pulmonary Fibrosis (IPF), obtain detailed clinical and personal information for risk factor assessment and blood for potential biomarkers. Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Project; University of Sydney; University of Tasmania.
  • GRANT
    Partnership with the Australian Lung Foundation for Lung Cancer PhD Scholarship
    1 Sep 2013 - 30 Nov 2017
    People funded by this grant:
    • Walters H,
    • Sohal S
    Project Total: $45,000; This project will continue work on airway inflammation and remodelling in smokers. Funded by: Lung Foundation Australia - Scholarship-PhD ($45,000); University of Tasmania.
  • GRANT
    Australasian Airways Satellite: Satellites of Cochrane Review Groups (SCRGs) NHMRC funding round 6
    1 Jul 2013 - 30 Jun 2017
    People funded by this grant:
    • Walters J,
    • Walters H
    Project Total: $92,000; Funded by: National Health & Medical Research CouncilNational Health & Medical Research Council - Grant-Satellites of Cochrane Review Groups ($184,000); University of Tasmania.
  • GRANT
    Australian IPF Registry State Coordinator (Tas)
    1 Jan 2013 - 30 Jun 2018
    People funded by this grant:
    • Walters H
    Project Total: $75,758; Funded by: Lung Foundation Australia - Grant ($75,758); University of Tasmania.